EZH2 and triple-A syndrome: Cumulatively, our findings suggest that the maternal HFD-induced augmentation of osteoclastogenesis through enhanced EZH2 activity may be a common epigenetic basis for AAA progression and osteolytic bone destruction in specific types of cancers and may facilitate a further understanding of osteoclast-associated chronic inflammatory disorders triggered by the maternal HFD intake.